5mg

Chymostatin

GenCRISPR™ Ultra eSpCas9-2NLS-GMP is utilized for CRISPR gene editing applications. The Cas9 nuclease forms a stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component. With the help of two nuclear localization signals (NLS) expressed with the Cas9 nuclease, the RNP complex enters the nucleus and cleaves target gene. When compared with a plasmid-based delivery system, the RNP delivery system has been observed to increase the on-target gene editing efficiency and decrease off-target effects.

The GenCRISPR™
Ultra eSpCas9 product line provides customers with a selection of research use,
basic GMP and GMP compliant Cas9 nucleases. The Cas9 protein can be formed with
the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP complex
to perform gene editing has been shown to reduce the challenges encountered
with other CRISPR gene editing techniques such as viral and plasmid delivery.
Challenges include off-target effects, cell viability and transcription/translational
challenges.

GenCRISPR™
Ultra eSpCas9-2NLS is a mutant form of Cas9 nuclease and is produced by
expression in an E. coli strain
carrying a plasmid encoding the eSpCas9 gene from Streptococcus pyogenes with double-ended nuclear localization
signal (NLS). GenCRISPR™ Ultra eSpCas9-2NLS delivers higher fidelity and less
off-target activity than wild-type SpCas9 nuclease.

The GenCRISPR™
Ultra eSpCas9 product line provides customers with a selection of research use,
basic GMP and GMP compliant Cas9 nucleases. The Cas9 protein can be formed with
the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP complex
to perform gene editing has been shown to reduce the challenges encountered
with other CRISPR gene editing techniques such as viral and plasmid delivery.
Challenges include off-target effects, cell viability and transcription/translational
challenges.

GenCRISPR™ Ultra eSpCas9-N-NLS
Research, tag-free is a mutant form of Cas9
nuclease and is produced by expression in an E. coli strain carrying a plasmid encoding the eSpCas9 gene from Streptococcus pyogenes with an N-terminal
nuclear localization signal (N-NLS). GenCRISPR™ Ultra eSpCas9-N-NLS Research,
tag-free delivers higher fidelity
and less off-target activity than wild-type SpCas9 nuclease.

GenCRISPR™ Ultra NLS-Cas9-GMP is utilized for CRISPR gene editing applications. It is manufactured in compliance with ISO 13485 and GMP quality management system standards and with stringent process controls and complete documentation records. This product is a ideal choice for most CRISPR gene editing applications where high editing efficiency is preferred.

The
GenCRISPR™ Ultra Cas9 product line provides customers with a selection of
research use, GMP preclinical and GMP compliant Cas9 nucleases. The Cas9
protein can be formed with the guide RNA into a ribonucleoprotien (RNP)
complex. The use of an RNP complex to perform gene editing has been shown to
reduce the challenges encountered with other CRISPR gene editing techniques
such as viral and plasmid delivery. Challenges include off-target effects, cell
viability and trascprition/translational challenges.

GenCRISPR™ Ultra Cas9 is
produced by expression in an E. coli
strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with an N-terminal nuclear localization
signal (NLS).